Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
Conditions
Interventions
REPLAGAL
Locations
28
Canada
M.A.G.I.C. Clinic Ltd. Metabolics and Genetics in Calgary
Calgary, Canada
Queen Elizabeth II Health Sciences Center
Halifax, Canada
Turun Yliopistollinen Keskussairaala
Turku, Finland
Vaasan Keskussairaala
Vaasa, Finland
Charité - Universitätsklinikum
Berlin, Germany
SphinCS
Höchheim, Germany
Start Date
December 28, 2021
Primary Completion Date
December 16, 2022
Completion Date
December 16, 2022
Last Updated
June 17, 2024
NCT07382128
NCT05923788
NCT07277361
NCT04252066
NCT06226987
NCT06065852
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions